-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Downgrades ADC Therapeutics to Sector Perform, Lowers Price Target to $2

Benzinga·06/04/2026 13:19:13
Listen to the news
RBC Capital analyst Leonid Timashev downgrades ADC Therapeutics (NYSE:ADCT) from Outperform to Sector Perform and lowers the price target from $6 to $2.